|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Weigelt B, Peterse JL and van’t Veer LJ:
Breast cancer metastasis: markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Bogenrieder T and Herlyn M: Axis of evil:
molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kuespert K, Pils S and Hauck CR: CEACAMs:
their role in physiology and pathophysiology. Curr Opin Cell Biol.
18:565–571. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Obrink B: CEA adhesion molecules:
multifunctional proteins with signal-regulatory properties. Curr
Opin Cell Biol. 9:616–626. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Gray-Owen SD and Blumberg RS: CEACAM1:
contact-dependent control of immunity. Nat Rev Immunol. 6:433–446.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Huang J, Hardy JD, Sun Y and Shively JE:
Essential role of biliary glycoprotein (CD66a) in morphogenesis of
the human mammary epithelial cell line MCF10F. J Cell Sci.
112:4193–4205. 1999.PubMed/NCBI
|
|
8.
|
Horst AK and Wagener C: CEA-Related CAMs.
Handb Exp Pharmacol. 283–341. 2004. View Article : Google Scholar
|
|
9.
|
Nittka S, Gunther J, Ebisch C,
Erbersdobler A and Neumaier M: The human tumor suppressor CEACAM1
modulates apoptosis and is implicated in early colorectal
tumorigenesis. Oncogene. 23:9306–9313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Singer BB, Scheffrahn I and Obrink B: The
tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is
differently expressed in proliferating and quiescent epithelial
cells and regulates cell proliferation. Cancer Res. 60:1236–1244.
2000.
|
|
11.
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: CEACAM6 gene silencing impairs anoikis resistance and
in vivo metastatic ability of pancreatic adenocarcinoma cells.
Oncogene. 23:465–473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Blumenthal RD, Leon E, Hansen HJ and
Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in
primary and metastatic cancers. BMC Cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Singer BB, Scheffrahn I, Kammerer R,
Suttorp N, Ergun S and Slevogt H: Deregulation of the CEACAM
expression pattern causes undifferentiated cell growth in human
lung adenocarcinoma cells. PLoS One. 5:e87472010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chevinsky AH: CEA in tumors of other than
colorectal origin. Semin Surg Oncol. 7:162–166. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Chan CH and Stanners CP: Recent advances
in the tumour biology of the GPI-anchored carcinoembryonic antigen
family members CEACAM5 and CEACAM6. Curr Oncol. 14:70–73. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hostetter RB, Campbell DE, Chi KF, et al:
Carcinoembryonic antigen enhances metastatic potential of human
colorectal carcinoma. Arch Surg. 125:300–304. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Blumenthal RD, Hansen HJ and Goldenberg
DM: Inhibition of adhesion, invasion, and metastasis by antibodies
targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen).
Cancer Res. 65:8809–8817. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Jantscheff P, Terracciano L, Lowy A, et
al: Expression of CEACAM6 in resectable colorectal cancer: a factor
of independent prognostic significance. J Clin Oncol. 21:3638–3646.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ballesta AM, Molina R, Filella X, Jo J and
Gimenez N: Carcinoembryonic antigen in staging and follow-up of
patients with solid tumors. Tumour Biol. 16:32–41. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Scorilas A, Chiang PM, Katsaros D, Yousef
GM and Diamandis EP: Molecular characterization of a new gene,
CEAL1, encoding for a carcinoembryonic antigen-like protein with a
highly conserved domain of eukaryotic translation initiation
factors. Gene. 310:79–89. 2003. View Article : Google Scholar
|
|
21.
|
Weigel MT and Dowsett M: Current and
emerging biomarkers in breast cancer: prognosis and prediction.
Endocr Relat Cancer. 17:R245–R262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Harris L, Fritsche H, Mennel R, et al:
American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer. J
Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Henderson IC and Patek AJ: The
relationship between prognostic and predictive factors in the
management of breast cancer. Breast Cancer Res Treat. 52:261–288.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Bertos NR and Park M: Breast cancer - one
term, many entities? J Clin Invest. 121:3789–3796. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kinsel LB, Szabo E, Greene GL, Konrath J,
Leight GS and McCarty KS Jr: Immunocytochemical analysis of
estrogen receptors as a predictor of prognosis in breast cancer
patients: comparison with quantitative biochemical methods. Cancer
Res. 49:1052–1056. 1989.PubMed/NCBI
|
|
26.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
27.
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: a new bioinformatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thurlimann B and Senn HJ: Strategies for subtypes - dealing
with the diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Poola I, Shokrani B, Bhatnagar R, DeWitty
RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell
adhesion molecule 6 oncoprotein in atypical ductal hyperplastic
tissues is associated with the development of invasive breast
cancer. Clin Cancer Res. 12:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Maraqa L, Cummings M, Peter MB, et al:
Carcinoembryonic antigen cell adhesion molecule 6 predicts breast
cancer recurrence following adjuvant tamoxifen. Clin Cancer Res.
14:405–411. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Gaur S, Shively JE, Yen Y and Gaur RK:
Altered splicing of CEACAM1 in breast cancer: identification of
regulatory sequences that control splicing of CEACAM1 into long or
short cytoplasmic domain isoforms. Mol Cancer. 7:462008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Zhou J, Zhang L, Gu Y, et al: Dynamic
expression of CEACAM7 in precursor lesions of gastric carcinoma and
its prognostic value in combination with CEA. World J Surg Oncol.
9:1722011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ilantzis C, DeMarte L, Screaton RA and
Stanners CP: Deregulated expression of the human tumor marker CEA
and CEA family member CEACAM6 disrupts tissue architecture and
blocks colonocyte differentiation. Neoplasia. 4:151–163. 2002.
View Article : Google Scholar
|
|
34.
|
Serra S, Asa SL, Bamberger AM, Wagener C
and Chetty R: CEACAM1 expression in pancreatic endocrine tumors.
Appl Immunohistochem Mol Morphol. 17:286–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Fredholm H, Eaker S, Frisell J, Holmberg
L, Fredriksson I and Lindman H: Breast cancer in young women: poor
survival despite intensive treatment. PLoS One. 4:e76952009.
View Article : Google Scholar : PubMed/NCBI
|
